Circulating NSE levels illustrate statistically significant variations in SCLC according to the status of patient: elevated pre-treatment levels will initially increase after chemotherapy (tumor lysis syndrome), followed by a decrease in responder patients (chemotherapy sensitive tumors) [45]. The gene discussed is ENO2; the disease is small cell lung carcinoma.